[1] Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS medicine 2014;11(4):e1001624. doi:...
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: Liver-Related Clinical Outcomes and Subgroup Analysis by Liver Cirrhosis Status Hyung Joon Kim,Chung-Ang University College of Medicine ➢ 背景及目的:本研究评估了...
肝细胞癌（hepatocellular carcinoma，HCC）是全球第五大最常见的癌症，也是癌症相关死亡的第二大原因。乙型肝炎病毒（hepatitis B virus，HBV）感染是HCC的主要危险因素之一。部分患者即使经过治疗并取得了HBsAg血清学清除，但仍有可能发生HCC。在2022年AASLD肝病年会上，美国斯坦福大学的Mindie Nguyen教授与法国巴黎第13大...
Level B Data derived from a single randomized trial, or nonrandomized studies. Level C Only consensus opinion of experts, case studies, or standard- of-care. Table 2. Differential Diagnosis of Ascites Cirrhosis Alcoholic hepatitis Heart failure ...
Dictionary, Encyclopedia and Thesaurus - The Free Dictionary13,881,820,183visits served TheFreeDictionary Google ? Keyboard Word / Article Starts with Ends with Text EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусский...
AASLD PRACTICE GUIDELINESDiagnosis, Management, and Treatment of Hepatitis C:An UpdateMarc G. Ghany,1Doris B. Strader,2D,人人文库,
3.Liu M, Tseng TC, Jun DW, et al. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol Int. 2021;15(1):71-81. 4.Park J, Le AK, Tseng TC, et al. Progression Rates by Age, Sex, Treatment, and...
AASLDPRACTICEGUIDELINECorrectionstoAASLDGuidelinesonChronicHepatitisBTotheEditor:WewouldappreciateifcorrectionstoTables2and10inLok..
HBV infection is a global public health threat. The World Health Organization (WHO) estimates that approximately 300 million people worldwide are living with hepatitis B and 1.1 million deaths occur annually due to hepatitis B,...
Background Antiviral treatment criteria are based on disease progression risk, and hepatocellular carcinoma (HCC) surveillance recommendations for patients with chronic hepatitis B (CHB) without cirrhosis is based on an annual incidence threshold of 0.2%. However, accurate and precise disease progression ...